C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	KREJČÍ Pavel
Year of publication	2019
Type	Article in Periodical
Magazine / Source	New England Journal of Medicine
MU Faculty or unit	Faculty of Medicine
Citation
Web	http://dx.doi.org/10.1056/NEJMc1910394
Doi	http://dx.doi.org/10.1056/NEJMc1910394
Keywords	Achondroplasia; C-type natriuretic peptide
Description	Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications.
Related projects:	Molekulární a buněčná biologie pro biomedicínské vědy